Recombinant Mouse Meprin A subunit alpha (Mep1a)

What is the basic structure of recombinant mouse Meprin alpha subunit?

Recombinant mouse Meprin alpha subunit (Mep1a) is a zinc-dependent metalloendopeptidase belonging to the astacin family of proteases. The protein spans amino acids Val34-Arg615 and typically includes a C-terminal 10-His tag for purification purposes. The full structure comprises multiple domains: a signal peptide, propeptide, catalytic domain containing the zinc-binding active site motif (HExxHxxGxxH/N), a MAM (meprin A5 protein tyrosine phosphatase μ) domain, a MATH (meprin-and-TRAF homology) domain, an intervening AM (after MATH) domain, an I (inserted) domain, an EGF (epidermal growth factor)-like domain, and in native protein, a transmembrane domain and cytosolic domain . When expressed recombinantly, the protein has an observed molecular weight of approximately 80 kDa under reducing conditions, though its theoretical molecular weight is 68 kDa, with the difference likely attributable to glycosylation .

What oligomeric states can recombinant Meprin alpha form, and how do they affect function?

Meprin alpha can form multiple oligomeric states with distinct functional properties. In its simplest form, it exists as homodimers stabilized by disulfide bridges. These homodimers can further associate non-covalently to form large oligomeric assemblies, with reported sizes of up to 6 MDa. Recent cryo-EM studies have revealed that meprin α forms a giant, flexible, left-handed helical assembly approximately 22 nm in diameter . The oligomerization is mediated by MAM domain interactions, and site-directed mutagenesis studies have shown that disrupting the intermolecular disulfide bridge (e.g., C308A mutation) results in predominantly monomeric forms . The oligomeric state significantly influences substrate accessibility, catalytic efficiency, and potentially tissue distribution. For in vitro studies, researchers should characterize the oligomeric state of their recombinant preparation to ensure experimental consistency and proper interpretation of results.

What expression systems are optimal for producing functional recombinant mouse Meprin alpha?

The most successful expression system for producing functional recombinant mouse Meprin alpha is the baculovirus-infected insect cell system, particularly Spodoptera frugiperda Sf21 cells . This eukaryotic expression system provides several advantages: (1) it enables proper folding of the complex multi-domain structure, (2) it supports essential post-translational modifications, particularly glycosylation, which affects stability and activity, and (3) it generally yields higher amounts of active protein compared to bacterial systems. When using this system, researchers should optimize infection conditions (MOI, harvest time) and culture parameters (media composition, temperature) to maximize yield while maintaining protein quality. Alternative mammalian expression systems using HEK293 or CHO cells can also produce functional protein but may have different glycosylation patterns that affect specific activities or stability profiles.

What purification strategies yield the highest purity and activity of recombinant Meprin alpha?

A multi-step purification strategy is recommended for obtaining high-purity, active recombinant Meprin alpha. For His-tagged constructs (common in commercial preparations), the following approach is effective:

• Initial capture using immobilized metal affinity chromatography (IMAC) with Ni-NTA or Co-NTA resins

• Intermediate purification using ion exchange chromatography (typically anion exchange at pH >7.5)

• Polishing step using size exclusion chromatography to separate monomers, dimers, and higher oligomers

Throughout purification, buffer conditions should be optimized to maintain enzyme stability, typically including:

• 50 mM Tris or HEPES buffer (pH 7.5-8.0)

• 100-500 mM NaCl to maintain solubility

• Optional addition of 5-10% glycerol to prevent aggregation

For optimal activity, avoid chelating agents (EDTA) that would strip the catalytic zinc ion. Final preparations typically achieve >95% purity as assessed by SDS-PAGE under reducing conditions .

How can I verify the activation state of recombinant Meprin alpha preparations?

Recombinant Meprin alpha is initially expressed as a zymogen (pro-form) that requires proteolytic removal of the N-terminal propeptide for activation. Verification of activation status can be accomplished through:

• SDS-PAGE analysis: The pro-form has a higher molecular weight (approximately 6 kDa larger) than the active form due to the presence of the propeptide .

• Activity assays: Using fluorogenic peptide substrates such as Mca-YVADAPK(Dnp)-OH to measure enzymatic activity. The specific activity of properly activated mouse Meprin alpha should be >400 pmol/min/μg under standard assay conditions .

• N-terminal sequencing: To confirm precise removal of the propeptide at the correct site.

For recombinant preparations, activation can be achieved by limited proteolysis with trypsin (carefully optimized to prevent degradation of the mature enzyme), followed by inhibition of the trypsin with serine protease inhibitors like AEBSF . Commercial preparations may be supplied in either the pro-form or active form, and researchers should confirm the activation state before use in functional studies.

What are the optimal assay conditions for measuring mouse Meprin alpha enzymatic activity?

The optimal conditions for assaying mouse Meprin alpha activity include:

• Buffer composition: 50 mM Tris, pH 9.0 with 1 M NaCl

• Temperature: 37°C is standard for physiological relevance

• Substrate: Fluorogenic peptides such as Mca-YVADAPK(Dnp)-OH are commonly used

• Enzyme concentration: Typically 0.5-5 nM active enzyme, depending on specific activity

• Activation: If using pro-form, activation with trypsin (10-50 ng/μl) for 30 minutes at 37°C, followed by trypsin inhibition with AEBSF (1 mM final concentration)

Activity is typically measured by monitoring the increase in fluorescence over time (excitation/emission wavelengths dependent on the specific fluorophore used). Kinetic parameters (Km, kcat) should be determined under conditions where substrate consumption is linear with time and proportional to enzyme concentration (typically <10% substrate consumption). For comparative studies between preparations or experiments, standardized specific activity measurements are essential for normalization.

How does substrate specificity of mouse Meprin alpha compare to human Meprin alpha and Meprin beta?

Mouse Meprin alpha demonstrates both similarities and differences in substrate specificity compared to human Meprin alpha and Meprin beta:

These differences in substrate specificity arise from structural variations in the active site and substrate-binding regions. When designing experiments to study specific substrates or inhibitors, researchers should consider these species-specific differences, particularly when translating findings between mouse models and human systems .

What endogenous inhibitors regulate Meprin alpha activity, and how can they be used experimentally?

Several endogenous inhibitors regulate Meprin alpha activity, with important implications for experimental design:

• Fetuin-B: A potent natural inhibitor of Meprin alpha that binds to the active site. Recent structural studies have revealed the mechanism of inhibition through complex formation . Recombinant fetuin-B can be used as a specific control inhibitor in activity assays.

• Tissue inhibitors of metalloproteinases (TIMPs): Certain TIMPs can modulate Meprin activity, though with lower specificity than for MMPs.

• Alpha-2-macroglobulin: This broad-spectrum protease inhibitor can trap active Meprin alpha in plasma and extracellular fluids.

Experimentally, these inhibitors can be used to:

• Validate the specificity of activity measurements

• Study regulatory mechanisms in complex biological samples

• Develop positive controls for inhibitor screening assays

• Investigate the physiological regulation of Meprin alpha in tissues where these inhibitors are co-expressed

When using these inhibitors, titration experiments should be performed to determine IC50 values and ensure complete inhibition where required.

How can recombinant Meprin alpha be used to study acute kidney injury mechanisms?

Recombinant Meprin alpha serves as a valuable tool for investigating acute kidney injury (AKI) mechanisms through several approaches:

• In vitro modeling: Treating cultured renal proximal tubule epithelial cells with recombinant Meprin alpha to study direct effects on cell viability, cytoskeletal organization, and tight junction integrity. This approach helps elucidate how Meprin alpha contributes to tubular damage during AKI.

• Substrate identification: Using purified recombinant Meprin alpha to identify kidney-specific substrates through techniques like TAILS (Terminal Amine Isotopic Labeling of Substrates) or analysis of cleavage sites in candidate proteins. This has revealed that Meprin alpha can cleave important renal proteins including cytoskeletal components and tight junction proteins.

• Inhibitor testing: Screening and validating small molecule inhibitors against recombinant Meprin alpha as potential therapeutic agents for AKI, where meprin activity is often dysregulated.

• Structure-function studies: Using site-directed mutagenesis of recombinant Meprin alpha to understand how specific domains contribute to substrate recognition and catalytic activity in the context of kidney injury.

Importantly, Meprin A (comprising α- and β-subunits) is abundantly expressed in the apical membranes of renal proximal tubules, and its dysregulated activity has been implicated in the pathogenesis of AKI . Using recombinant Meprin alpha in these research applications has provided significant insights into the molecular mechanisms underlying tubular damage during kidney injury.

What experimental approaches can be used to study Meprin alpha oligomerization and its functional significance?

The unique oligomerization properties of Meprin alpha can be studied using multiple complementary approaches:

These approaches can reveal how oligomerization affects Meprin alpha's enzymatic activity, substrate accessibility, stability, and biological function in different physiological contexts.

How can recombinant Meprin alpha be used to develop selective inhibitors for therapeutic applications?

Recombinant Meprin alpha serves as an essential tool in the development of selective inhibitors through a systematic drug discovery process:

• High-throughput screening (HTS):

  • Using purified recombinant Meprin alpha in fluorescence-based activity assays to screen compound libraries

  • Developing specialized assay conditions that enable identification of selective inhibitors versus other metalloproteases

  • Validation of hits using secondary biochemical and cell-based assays

• Structure-based drug design:

  • Utilizing structural information from cryo-EM studies of Meprin alpha complexes with prototype inhibitors

  • In silico docking and virtual screening to identify compounds that bind the active site or allosteric sites

  • Rational design of inhibitors based on known substrate preferences

• Selectivity profiling:

  • Comparative inhibition studies against related proteases (Meprin beta, MMPs, ADAMs) to establish selectivity profiles

  • Counter-screening against a panel of metalloproteases to ensure target specificity

  • Assessment of structure-activity relationships to optimize selectivity

• Efficacy testing:

  • Validation of lead compounds in cellular models where Meprin alpha activity is implicated in pathology

  • Testing in ex vivo tissue preparations (e.g., kidney slices for AKI applications)

  • Progression to in vivo models with appropriate pharmacokinetic properties

The development of selective Meprin alpha inhibitors has therapeutic potential for conditions including acute kidney injury, fibrotic disorders, and inflammatory pathologies where dysregulated Meprin activity contributes to disease progression.

What are the critical factors for maintaining stability and activity of recombinant Meprin alpha in laboratory settings?

Maintaining the stability and activity of recombinant Meprin alpha requires careful attention to several factors:

• Storage conditions:

  • Store at -70°C for long-term preservation

  • Avoid repeated freeze-thaw cycles (limit to <5)

  • For working stocks, store at -20°C in small aliquots with 10-20% glycerol

  • Stability timeline: 6 months from date of receipt at -20°C to -70°C as supplied; 3 months under sterile conditions after opening

• Buffer composition:

  • Maintain pH between 7.5-9.0 (optimal activity at pH 9.0)

  • Include sufficient salt concentration (typically 0.1-1M NaCl) to prevent aggregation

  • Add stabilizers such as glycerol (5-20%) for freeze-thaw protection

  • Avoid metal chelators like EDTA that would strip the essential zinc ion

  • Consider adding low concentrations of zinc (1-5 μM ZnCl₂) to prevent zinc loss

• Handling practices:

  • Use low-binding tubes and pipette tips to minimize protein adsorption

  • Keep on ice when thawed for experiments

  • Filter sterilize (0.22 μm) for longer-term storage of working solutions

  • Monitor activity periodically using standard substrate assays

• Activation considerations:

  • If using the zymogen form, standardize activation protocols (trypsin concentration, incubation time, temperature)

  • Completely inhibit the activating protease after activation

  • Consider pre-activating only the amount needed for immediate experiments

By carefully controlling these factors, researchers can maintain consistent enzyme activity across experiments and maximize the usable lifetime of valuable recombinant protein preparations.

How should I design controls for experiments involving recombinant Meprin alpha activity?

Proper experimental controls are critical for studies involving recombinant Meprin alpha activity:

• Negative controls:

  • Heat-inactivated enzyme (95°C for 10 minutes)

  • Metal chelation control (addition of EDTA to sequester zinc and inhibit activity)

  • Specific inhibitor controls (e.g., actinonin, fetuin-B, or validated small molecule inhibitors)

  • Buffer-only controls to account for spontaneous substrate hydrolysis

  • Inactive mutant controls (e.g., E-to-A substitution in the active site HExxH motif)

• Positive controls:

  • Commercial standard of known activity for inter-experimental normalization

  • Parallel assays with well-characterized substrates to confirm enzyme functionality

  • Dose-response curves with known inhibitors to validate assay sensitivity

• Specificity controls:

  • Parallel assays with related metalloproteases to confirm selectivity of effects

  • Competitive substrate assays to verify binding site interactions

  • Substrate depletion controls to ensure linear reaction kinetics

• System validation controls:

  • Cell culture experiments should include both wild-type and Mep1a-knockout conditions

  • Tissue experiments should consider endogenous Meprin expression

  • Western blotting to verify protein expression levels in cellular systems

Implementing these controls ensures that observed effects can be confidently attributed to Meprin alpha activity rather than experimental artifacts or non-specific protease actions.

What are the key considerations when comparing results between different recombinant Meprin alpha preparations?

When comparing results between different recombinant Meprin alpha preparations, researchers should consider several potential sources of variation:

• Expression system differences:

  • Insect cell vs. mammalian cell expression may result in different glycosylation patterns

  • Codon optimization and vector design can affect protein folding and yield

  • Purification tags (His, GST, FLAG) may influence activity or oligomerization

• Protein characteristics to verify:

  • Activation state (zymogen vs. active form) - confirm by SDS-PAGE and activity assays

  • Oligomeric state - analyze by size exclusion chromatography or native PAGE

  • Purity level - verify by SDS-PAGE (should be >95%)

  • Specific activity - standardize using defined substrates under identical conditions

• Standardization approaches:

  • Normalize to protein concentration determined by quantitative methods (BCA, Bradford)

  • Calculate and compare specific activities rather than raw activity measurements

  • Use internal standards across experiments for normalization

  • Develop and share detailed SOPs for activity measurements within research groups

• Documentation requirements:

  • Record lot numbers and sources of commercial preparations

  • Document full sequences including any tags or mutations

  • Maintain detailed records of storage conditions and freeze-thaw cycles

  • Track activity measurements over time to detect stability issues

By systematically addressing these considerations, researchers can minimize variability and ensure reproducibility when comparing results obtained with different Meprin alpha preparations.

What are common causes of low activity in recombinant Meprin alpha preparations, and how can they be addressed?

Low activity in recombinant Meprin alpha preparations can stem from several issues, each with specific remediation strategies:

• Incomplete activation:

  • Problem: Insufficient conversion of zymogen to active form

  • Diagnosis: SDS-PAGE showing predominant higher MW band; low activity despite high protein concentration

  • Solution: Optimize activation protocol with carefully titrated trypsin concentration (10-50 ng/μl) and incubation time (30-60 minutes at 37°C)

• Zinc depletion:

  • Problem: Loss of essential catalytic zinc ion

  • Diagnosis: Activity recoverable by adding ZnCl₂ to reaction

  • Solution: Add 1-5 μM ZnCl₂ to storage and assay buffers; avoid strong chelators

• Protein misfolding/aggregation:

  • Problem: Improper folding during expression or aggregation during storage

  • Diagnosis: Visible precipitation; abnormal elution profile on size exclusion chromatography

  • Solution: Optimize expression conditions (temperature, induction); add stabilizers (glycerol, low concentrations of non-ionic detergents); use size exclusion chromatography to isolate properly folded fractions

• Inhibitor contamination:

  • Problem: Co-purification of endogenous inhibitors

  • Diagnosis: Activity increases after additional purification steps

  • Solution: Include additional ion exchange or hydrophobic interaction chromatography steps in purification; test different purification tag positions or types

• Unsuitable assay conditions:

  • Problem: Suboptimal pH, salt concentration, or temperature

  • Diagnosis: Activity varies dramatically with buffer conditions

  • Solution: Optimize assay conditions (pH 9.0, 1M NaCl for mouse Meprin alpha) ; standardize temperature control

By systematically evaluating and addressing these potential issues, researchers can significantly improve the activity and reliability of recombinant Meprin alpha preparations.

How can I troubleshoot unexpected substrate cleavage patterns when working with recombinant Meprin alpha?

Unexpected substrate cleavage patterns can complicate interpretation of Meprin alpha experiments. A systematic troubleshooting approach includes:

• Verify enzyme quality:

  • Assess purity by SDS-PAGE (>95% purity is recommended)

  • Confirm activity using standard substrates with known cleavage patterns

  • Check for contaminating proteases by including class-specific inhibitors in parallel assays

• Analyze cleavage products:

  • Use mass spectrometry to identify exact cleavage sites

  • Compare observed cleavage sites with known Meprin alpha preferences

  • Perform time-course studies to distinguish primary from secondary cleavage events

• Examine experimental variables:

  • Test different enzyme:substrate ratios to identify concentration-dependent effects

  • Vary incubation times to capture sequential cleavage events

  • Modify buffer conditions (pH, salt) which can alter substrate specificity

• Consider substrate conformation:

  • Native vs. denatured substrate can yield different cleavage patterns

  • Substrate oligomerization or complex formation may mask potential cleavage sites

  • Post-translational modifications on substrates can create or block cleavage sites

• Validate with complementary approaches:

  • Compare results with other proteolytic assays

  • Use selective inhibitors to confirm Meprin alpha-specific cleavage

  • Validate findings in cellular systems with genetic knockdown/knockout controls

What strategies can address the challenges of working with the complex oligomeric structure of Meprin alpha in biochemical and cellular studies?

The complex oligomeric structure of Meprin alpha presents unique challenges in research settings. These challenges can be addressed through several strategies:

• Controlling oligomeric state:

  • Generate monomeric variants through point mutations (e.g., C308A) that disrupt intermolecular disulfide bridges

  • Use size exclusion chromatography to isolate specific oligomeric species

  • Develop buffer conditions that favor particular assembly states

• Visualization approaches:

  • Employ negative-stain electron microscopy for rapid assessment of oligomeric structures

  • Use fluorescently labeled protein to track oligomerization in real-time

  • Apply super-resolution microscopy for cellular localization of oligomers

• Functional discrimination:

  • Design substrate accessibility assays that can distinguish between oligomeric forms

  • Use cross-linking approaches to stabilize transient assemblies

  • Develop conformation-specific antibodies that recognize particular oligomeric states

• Cellular expression strategies:

  • Create inducible expression systems to control oligomerization timing

  • Co-express with subunit-specific chaperones to guide assembly

  • Use split fluorescent protein approaches to monitor oligomerization in living cells

• Computational approaches:

  • Apply molecular dynamics simulations to predict oligomerization interfaces

  • Model substrate access to active sites in different oligomeric forms

  • Design oligomerization-disrupting peptides based on interface structures

These strategies enable researchers to work effectively with Meprin alpha's complex quaternary structure, facilitating more precise studies of its biochemical properties and cellular functions.